Therefore, on the basis of the principle we describe here of targeting an axis of the NF-κB pathway with cancer-restricted function, rather than NF-κB globally, delineating these mechanisms could provide new strategies for targeting NF-κB in a disease-specific manner also in GADD45β-independent, NF-κB-addicted malignancies and, perhaps, nonmalignant NF-κB-driven pathologies. This evidence concerns the gene NFKB1 and cancer.